Get the Stockscreener App
0.6613
2.56%
0.0164
Bioxcel Therapeutics Inc stock is traded at $0.6613, with a volume of 154.35K.
It is up +2.56% in the last 24 hours and up +13.10% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$0.6449
Open:
$0.63
24h Volume:
154.35K
Relative Volume:
0.32
Market Cap:
$26.57M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.093
EPS:
-7.11
Net Cash Flow:
$-155.03M
1W Performance:
-6.95%
1M Performance:
+13.10%
6M Performance:
-74.26%
1Y Performance:
-85.75%
1-Day Range:
$0.63
$0.6699
1-Week Range:
$0.6201
$0.83
52-Week Range:
$0.505
$5.6199
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - Yahoo Finance
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com
BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World
BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN
BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia
BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India
BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan
BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia
BioXcel Therapeutics reports executive transition - Investing.com India
Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily
BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia
BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com Australia
BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa
Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com
BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com
BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com
BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com
BTAI Shares Experience Decline in Value - Knox Daily
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
The Potential Rise in the Price of BioXcel Therapeutics Inc (BTAI) following insiders activity - Knox Daily
BioXcel Therapeutics Inc: Weathering Stock Market Storms with 24.56M Market Cap - The InvestChronicle
Taking on analysts’ expectations and winning: BioXcel Therapeutics Inc (BTAI) - SETE News
BioXcel Therapeutics stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia
BioXcel Therapeutics stock hits 52-week low at $0.53 - Investing.com
BTAI underperforms with a -2.28 decrease in share price - US Post News
Bank of New York Mellon Corp Buys 49,863 Shares of XBiotech Inc. (NASDAQ:XBIT) - Defense World
Is it a good time to sell Xcel Energy, Inc. [XEL] shares after an insider sold 2,041 shares? - Knox Daily
Blair William & Co. IL Has $2.01 Million Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World
New Haven-based BioXcel faces delisting from Nasdaq stock exchange - Hartford Business Journal
Gaining Ground: BioXcel Therapeutics Inc (BTAI) Closes Lower at 0.58, Down -12.13 - The Dwinnex
Charting the Course: BioXcel Therapeutics Inc’s BTAI Stock Prospects - The InvestChronicle
Xcel Energy Inc. (NASDAQ:XEL) Shares Acquired by Sei Investments Co. - Defense World
Gabelli Funds LLC Sells 12,283 Shares of Xcel Energy Inc. (NASDAQ:XEL) - Defense World
BlackSky target adjusted to $15 from $2.50 at H.C. Wainwright - TipRanks
Summit Trail Advisors LLC Boosts Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World
BlueLinx Holdings Inc. (NYSE:BXC) Shares Purchased by Massachusetts Financial Services Co. MA - Defense World
BioXcel Therapeutics faces Nasdaq delisting risk over share price - Investing.com India
BioXcel Therapeutics faces Nasdaq delisting risk over share price By Investing.com - Investing.com Canada
Meiji Yasuda Asset Management Co Ltd. Has $1.13 Million Holdings in Xcel Energy Inc. (NASDAQ:XEL) - Defense World
New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - CT Insider
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):